• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域的构象变化及基于结构数据的B细胞抗原表位预测

Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data.

作者信息

Khare Sangeeta, Azevedo Marli, Parajuli Pravin, Gokulan Kuppan

机构信息

Division of Microbiology, National Center for Toxicological Research, United States-Food and Drug Administration, Jefferson, AR, United States.

出版信息

Front Artif Intell. 2021 Mar 25;4:630955. doi: 10.3389/frai.2021.630955. eCollection 2021.

DOI:10.3389/frai.2021.630955
PMID:33842877
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8027118/
Abstract

COVID-19, the illness caused by the SARS-CoV-2 virus, is now a worldwide pandemic with mortality in hundreds of thousands as infections continue to increase. Containing the spread of this viral infection and decreasing the mortality rate is a major challenge. Identifying appropriate antigenic epitopes from the viral proteins is a very important task for vaccine production and the development of diagnostic kits and antibody therapy. A novel antigenic epitope would be specific to the SARS-CoV-2 virus and can distinguish infections caused by common cold viruses. In this study two approaches are employed to identify both continuous and conformational B-cell antigenic epitopes. To achieve this goal, we modeled a complete structure of the receptor binding domain (RBD) of the spike protein using recently deposited coordinates (6vxx, 6vsb, and 6w41) in the protein data bank. In addition, we also modeled the RBD-ACE2 receptor complex for SARS-CoV-2 using the SARS-CoV RBD-ACE2 complex (3D0J) as a reference model. Finally, structure based predicted antigenic epitopes were compared to the ACE2 binding region of RBD of SARS-CoV-2. The identified conformational epitopes show overlaps with the ACE2-receptor binding region of the RBD of SARS-CoV-2. Strategies defined in the current study identified novel antigenic epitope that is specific to the SARS-CoV-2 virus. Integrating such approach in the diagnosis can distinguish infections caused by common cold viruses from SARS-CoV-2 virus.

摘要

新型冠状病毒肺炎(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的疾病,随着感染人数持续增加,现已成为全球大流行疾病,导致数十万人死亡。控制这种病毒感染的传播并降低死亡率是一项重大挑战。从病毒蛋白中识别合适的抗原表位对于疫苗生产、诊断试剂盒的开发以及抗体治疗来说是一项非常重要的任务。一种新型抗原表位将对SARS-CoV-2病毒具有特异性,并且能够区分由普通感冒病毒引起的感染。在本研究中,采用了两种方法来识别连续和构象性B细胞抗原表位。为实现这一目标,我们利用最近存入蛋白质数据库的坐标(6vxx、6vsb和6w41)对刺突蛋白受体结合域(RBD)的完整结构进行建模。此外,我们还以SARS-CoV RBD-ACE2复合物(3D0J)作为参考模型,对SARS-CoV-2的RBD-ACE2受体复合物进行建模。最后,将基于结构预测的抗原表位与SARS-CoV-2 RBD的ACE2结合区域进行比较。所识别的构象表位与SARS-CoV-2 RBD的ACE2受体结合区域存在重叠。本研究中定义的策略识别出了对SARS-CoV-2病毒具有特异性的新型抗原表位。将这种方法整合到诊断中可以区分普通感冒病毒引起的感染和SARS-CoV-2病毒引起的感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/57eea4a28315/frai-04-630955-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/f84c8d88f901/frai-04-630955-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/61c43cf8589b/frai-04-630955-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/9dab2f78a0be/frai-04-630955-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/122a19f9fe89/frai-04-630955-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/ee993648e257/frai-04-630955-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/57eea4a28315/frai-04-630955-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/f84c8d88f901/frai-04-630955-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/61c43cf8589b/frai-04-630955-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/9dab2f78a0be/frai-04-630955-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/122a19f9fe89/frai-04-630955-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/ee993648e257/frai-04-630955-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85a4/8027118/57eea4a28315/frai-04-630955-g0006.jpg

相似文献

1
Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域的构象变化及基于结构数据的B细胞抗原表位预测
Front Artif Intell. 2021 Mar 25;4:630955. doi: 10.3389/frai.2021.630955. eCollection 2021.
2
Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein.特异性识别新型冠状病毒刺突蛋白受体结合域线性表位的兔单克隆抗体。
Vaccines (Basel). 2021 Jul 28;9(8):829. doi: 10.3390/vaccines9080829.
3
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.对一名 SARS-CoV-2 感染者的分析显示,产生了具有有限体细胞突变的强效中和抗体。
Immunity. 2020 Jul 14;53(1):98-105.e5. doi: 10.1016/j.immuni.2020.06.001. Epub 2020 Jun 8.
4
Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域(RBD)与人血管紧张素转换酶2(ACE2)蛋白-蛋白相互作用的生物力学特性分析
bioRxiv. 2020 Jul 31:2020.07.31.230730. doi: 10.1101/2020.07.31.230730.
5
Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.高度保守的 ACE2 结合区域作为人类和哺乳动物之间 SARS-CoV-2 的受体。
Vet Q. 2020 Dec;40(1):243-249. doi: 10.1080/01652176.2020.1823522.
6
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.一种针对严重急性呼吸综合征冠状病毒 2 刺突蛋白 RBD 的疫苗可诱导保护性免疫。
Nature. 2020 Oct;586(7830):572-577. doi: 10.1038/s41586-020-2599-8. Epub 2020 Jul 29.
7
Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.基于表位的新型冠状病毒病 SARS-CoV-2 肽疫苗预测。
Virus Res. 2020 Oct 15;288:198082. doi: 10.1016/j.virusres.2020.198082. Epub 2020 Jul 1.
8
Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.用于阻断新冠病毒刺突蛋白受体结合域的潜在嵌合肽。
F1000Res. 2020 Jun 9;9:576. doi: 10.12688/f1000research.24074.1. eCollection 2020.
9
Mutations in SARS-CoV-2 Leading to Antigenic Variations in Spike Protein: A Challenge in Vaccine Development.导致新冠病毒刺突蛋白抗原变异的突变:疫苗研发中的一项挑战
J Lab Physicians. 2020 Aug;12(2):154-160. doi: 10.1055/s-0040-1715790. Epub 2020 Sep 1.
10
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.一名感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)患者体内中和抗体的特征分析
bioRxiv. 2020 May 12:2020.05.12.091298. doi: 10.1101/2020.05.12.091298.

引用本文的文献

1
Evaluating the Antiviral Potential of Polyherbal Formulation () Against Monkeypox Virus: Targeting E5, Poxin, and DNA Polymerase Through Multifaceted Drug Discovery Approaches.评估多草药配方()对猴痘病毒的抗病毒潜力:通过多方面药物发现方法靶向E5、痘毒素和DNA聚合酶。
Life (Basel). 2025 May 12;15(5):771. doi: 10.3390/life15050771.
2
Brewpitopes: a pipeline to refine B-cell epitope predictions during public health emergencies.酿酒位:公共卫生突发事件期间用于精炼 B 细胞表位预测的流水线。
Front Immunol. 2023 Dec 6;14:1278534. doi: 10.3389/fimmu.2023.1278534. eCollection 2023.
3
A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response.

本文引用的文献

1
IgA dominates the early neutralizing antibody response to SARS-CoV-2.IgA 在针对 SARS-CoV-2 的早期中和抗体反应中占主导地位。
Sci Transl Med. 2021 Jan 20;13(577). doi: 10.1126/scitranslmed.abd2223. Epub 2020 Dec 7.
2
Enhanced SARS-CoV-2 neutralization by dimeric IgA.二聚体 IgA 增强对 SARS-CoV-2 的中和作用。
Sci Transl Med. 2021 Jan 20;13(577). doi: 10.1126/scitranslmed.abf1555. Epub 2020 Dec 7.
3
Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years.未来 5 年的免疫史、疫苗接种和 SARS-CoV-2 的动态。
一种为可制造性设计的新型冠状病毒疫苗产生了意想不到的效力和持久的体液免疫反应。
Vaccines (Basel). 2023 Apr 12;11(4):832. doi: 10.3390/vaccines11040832.
4
Covid-19: virology, variants, and vaccines.新型冠状病毒肺炎:病毒学、变种与疫苗
BMJ Med. 2022 Apr 1;1(1):e000040. doi: 10.1136/bmjmed-2021-000040. eCollection 2022.
5
A review on human reproductive systems encountering with the severe acute respiratory syndrome coronavirus 2 infection.关于人类生殖系统遭遇严重急性呼吸综合征冠状病毒2感染的综述。
Int J Reprod Biomed. 2023 Feb 8;21(1):1-16. doi: 10.18502/ijrm.v21i1.12661. eCollection 2023 Jan.
6
S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进入细胞及感染性过程中的刺突蛋白(S蛋白)、血管紧张素转换酶2(ACE2)和宿主细胞蛋白酶;可溶性ACE2是双刃剑吗?一篇综述
Vaccines (Basel). 2023 Jan 17;11(2):204. doi: 10.3390/vaccines11020204.
7
Relationship between Humoral Response in COVID-19 and Seasonal Influenza Vaccination.新冠病毒感染(COVID-19)中的体液免疫反应与季节性流感疫苗接种之间的关系。
Vaccines (Basel). 2022 Sep 27;10(10):1621. doi: 10.3390/vaccines10101621.
8
An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation.静电导向的构象选择机制促进了 SARS-CoV-2 刺突蛋白的变异。
J Mol Biol. 2022 Jul 15;434(13):167637. doi: 10.1016/j.jmb.2022.167637. Epub 2022 May 17.
9
Emergence of SARS-CoV-2 Variants in the World: How Could This Happen?全球范围内严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的出现:这是如何发生的?
Life (Basel). 2022 Jan 28;12(2):194. doi: 10.3390/life12020194.
10
Structural Insights on the SARS-CoV-2 Variants of Concern Spike Glycoprotein: A Computational Study With Possible Clinical Implications.对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)关注变异株刺突糖蛋白的结构洞察:一项具有潜在临床意义的计算研究
Front Genet. 2021 Oct 22;12:773726. doi: 10.3389/fgene.2021.773726. eCollection 2021.
Science. 2020 Nov 13;370(6518):811-818. doi: 10.1126/science.abd7343. Epub 2020 Sep 21.
4
Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches.蛋白酶在 COVID-19 感染中的作用和有前景的治疗方法。
Biochem Pharmacol. 2020 Dec;182:114225. doi: 10.1016/j.bcp.2020.114225. Epub 2020 Sep 19.
5
Addressing COVID-19 Drug Development with Artificial Intelligence.利用人工智能应对新冠病毒药物研发
Adv Intell Syst. 2020 May;2(5):2000070. doi: 10.1002/aisy.202000070. Epub 2020 Apr 27.
6
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.一种交叉反应性人IgA单克隆抗体可阻断SARS-CoV-2刺突蛋白与血管紧张素转换酶2(ACE2)的相互作用。
Nat Commun. 2020 Aug 21;11(1):4198. doi: 10.1038/s41467-020-18058-8.
7
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.通过原型病原体准备实现的 SARS-CoV-2 mRNA 疫苗设计。
Nature. 2020 Oct;586(7830):567-571. doi: 10.1038/s41586-020-2622-0. Epub 2020 Aug 5.
8
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.评估 mRNA-1273 疫苗对 SARS-CoV-2 在非人类灵长类动物中的效果。
N Engl J Med. 2020 Oct 15;383(16):1544-1555. doi: 10.1056/NEJMoa2024671. Epub 2020 Jul 28.
9
Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19.基于中性粒细胞与淋巴细胞比值和IgG水平的免疫表型分析可预测COVID-19患者的疾病严重程度和预后。
Front Mol Biosci. 2020 Jul 3;7:157. doi: 10.3389/fmolb.2020.00157. eCollection 2020.
10
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.mRNA 疫苗对 SARS-CoV-2 的作用-初步报告。
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.